Independent US-licensed providers· US-licensed compounding pharmacy· HIPAA-safe intake· Discreet US shipping

2026-08-02 · 3 min read · Van Peptides Editorial

GHK-Cu: The Copper Peptide Behind the Skin and Hair Buzz

What the literature shows about GHK-Cu, the copper peptide studied for skin remodeling and hair follicle biology. Educational content, not medical advice.

Editorial illustration for GHK-Cu: The Copper Peptide Behind the Skin and Hair Buzz

GHK-Cu shows up constantly in skincare and hair-health conversations, but how much of that reputation is backed by real research, and how much is marketing borrowing a scientific-sounding name?

What we know from the literature

GHK-Cu is a naturally occurring tripeptide, glycyl-L-histidyl-L-lysine, bound to a copper ion. It circulates in human plasma and its levels decline with age, an observation that helped drive research interest in its role in tissue remodeling (Pickart & Margolina review, PMID 18644225). An early controlled study in a rat wound model found that GHK-Cu increased connective tissue accumulation compared to controls, one of the foundational findings behind its wound-healing reputation (Maquart et al., J Clin Invest, 1993, PMID 8227353).

The review literature also describes GHK-Cu increasing synthesis of collagen, elastin, and related growth factors, along with proliferation of fibroblasts and keratinocytes and an association with hair follicle size in some models. Outcomes are individual, and the strength of evidence varies considerably depending on whether a specific claim comes from a well-controlled human skin study or an early rodent wound model.

Skin: what the controlled studies show

Some of the most frequently cited GHK-Cu findings come from controlled studies on aged human skin, which reported improvements in skin tightness, elasticity, firmness, and the appearance of fine lines, wrinkles, and photodamage (Pickart & Margolina, PMID 18644225). These are meaningful, cosmetically relevant findings, but they describe average effects across study populations, not a guarantee for any one person’s skin. Individual results vary, and a US-licensed provider can talk through where you fall relative to the population studied and what a reasonable expectation looks like.

Hair: a smaller and more preliminary picture

The hair-related findings for GHK-Cu are less extensively studied than the skin data. Review sources mention improved hair transplant success and increased hair follicle size in some models, but this body of evidence is thinner than the skin literature and draws more heavily on smaller or animal-adjacent work. Individual results vary considerably here, and anyone considering GHK-Cu specifically for hair should treat the existing evidence as suggestive rather than conclusive, a distinction worth raising directly with a provider.

How to access it responsibly

  • Everything is available after a licensed-provider evaluation.
  • Peptides are compounded through a US-licensed compounding pharmacy.

Sources

  1. Pickart L, Margolina A. The human tri-peptide GHK and tissue remodeling. PMID 18644225 pubmed.ncbi.nlm.nih.gov/18644225/
  2. Maquart FX et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex GHK-Cu in rat experimental wounds. J Clin Invest. 1993;92(5):2368-76. doi:10.1172/JCI116842. PMID 8227353 pubmed.ncbi.nlm.nih.gov/8227353/

Common questions

Is GHK-Cu proven to regrow hair?

No single standard exists for that claim in the current literature; the hair-related evidence is more preliminary than the skin-related evidence. A licensed provider can discuss what is and is not established.

Is GHK-Cu FDA approved?

No. GHK-Cu is not FDA approved, and no FDA-approved brand-name version exists.

How is GHK-Cu typically accessed through Van Peptides?

It is available after a licensed-provider evaluation and, if prescribed, compounded through a US-licensed compounding pharmacy.

Can I use GHK-Cu topically instead of the compounded injectable form?

That is a clinical question specific to your goals and history; a US-licensed provider is best positioned to discuss the options and what the evidence supports for each.

Related reading